Human chorionic gonadotropin acts on the same receptor as luteinizing hormone, the pituitary signal that tells the testes to produce testosterone. That physiology is why it comes up in conversations about testicular function and fertility.
Labeled uses are specific. In men, chorionic gonadotropin labeling covers prepubertal cryptorchidism not due to anatomic obstruction and hypogonadotropic hypogonadism secondary to pituitary deficiency. Labeling is also explicit that it is not effective as a weight-loss therapy.
Where it fits for a particular man depends on the underlying diagnosis, whether fertility is a near-term goal, what the labs show, and current product availability. Uses outside labeled indications should be identified as such and discussed honestly rather than presented as routine.
Risks and limitations
- Labeled indications are narrow; other uses are off-label and should be described that way.
- Labeling states it is not effective for weight loss.
- Effects on fertility and testosterone differ depending on the underlying cause.
- Product availability and regulatory status can change and must be verified.
- This page does not state which therapies MMI offers.